La importancia del ácido alendronico en la mujer transexual reasignada (página 2)

5. Benoist M. Osteoporotic vertebral fractures. Neurological complications. In: Szpalski M, Gunzburg R, editors. Vertebral osteoporotic compression fractures. Philadelphia: Lippincot Williams & Wilkins, 2003: 81-86.

6. Black D,Finkelstein J.The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.NEJM2003;349(13)1207-1226..

7. Black DM, Cummings SR, Karpf, DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535.

8. Cauley JA et al., Osteoporos Int 2000;11:556-61. Díaz López JB, Naves Díaz ML, Gómez Alonso C, Cannata Andía JB. Epidemiología de la fractura vertebral osteoporótica e historia natural de la enfermedad, pág. 37-52. En: La fractura vertebral osteoporótica desde la perspectiva del clínico y el paciente, Medical & Marketing Communications, Madrid, 1999.

9. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99:144.

10. Chrischilles EA, Butter CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151: 2026.

11. Cuénod CA, Laredo JD, Chevret S, Hamze B, Naouri JF, Chapaux X et al. Acute vertebral collapse due to osteoporosis or malignancy: appearance on enhanced and gadolinium-enhanced MR images. Radiology 1996; 199: 541-549.

12. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998; 280:2077.

13. Cummings SR, Melton III LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.

14. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736.

15. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch Intern Med 1997; 157:2617.

16. Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005; 20: 1216-1222.

17. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18: 185S.

18. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R. Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Italy. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int. 2003 Aug; 73(2):133-9.

19. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92:1322.

20. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161:107.

21. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136:742.

22. Groen PC, Lubbge DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016.

23. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338:485.

24. Johnell O. Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality. J Int Med 1996; 239: 299.

25. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-589.

26. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Min Res 1994; 9: 1137-1141.

27. Kaplan FS, Scherl JD, Wisneski R, Cheatle M, Haddad JG. The cluster phenomenon in patients who have multiple vertebral compression fractures. Clin Orthop Relat Res 1993; 297: 161-167.

28. Knobel H, Díez A, Arnau D, Alier A, Ibáñez J, Campodarve I, Supervía A, Nogués X. Secuelas de la fractura osteoporótica de fémur en Barcelona. Med Clin 1992; 36: 750-756.

29. Lenchik L, Rogers LF, Delmas PD, Genant HK. Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. Am J Roentgenol 2004; 183: 949-958. Hirschberg GG, Williams KA, Byrd JE. Medical management of iliocostal pain. Geriatrics 1992; 47 62-67.

30. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997; 102:489.

31.  Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437.

32. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.

33. Lombardi I, Oliveira LM, Mayer AF, Jardim JR, Natour J. Evaluation of pulmonary function and quality of life in women with osteoporosis. Osteoporos Int 2005; in press.

34. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 1998; 128:253.

35. Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N. Diagnosis and management of vertebral fractures in elderly adults. Am J Med 2002; 113: 220-228.

36. Pither CE. Mechanisms of pain in osteoporotic vertebral compression fracture. In: Szpalski M, Gunzburg R, editors. Vertebral osteoporotic compression fractures. Philadelphia: Lippincott Williams & Wilkins, 2003: 73-79.

37. Riancho JA. Aplastamiento vertebral. In: Riancho JA, González-Macías J, editors. Manual práctico de osteoporosis y enfermedades del metabolismo mineral. Madrid: Jarpyo, 2004: 117-121.

38. Robert Lindsay,Felicia Cosman. Osteoporosis. Princicpios de Medicina Interna-Harrison, 2001vol 2:2063-2615.

39. Ross PD, Davis JW, Epstein RS, et al. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol 1994; 47:231.

40. Speed C. Low back pain. Br Med J 2004; 328: 1119- 1121.

41. Weber M, Uehlinger K, Gerber H. Osteoporotic vertebral compression fracture causing neurologic deficit. J Clin Rheumatol 2002; 8: 166-173.

42. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.

43. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineraldensity in the hip and vertebrae: four year randomized study. Am J Med 1995; 99:36.